Cabometyx

• Cabometyx is an oral medication that targets multiple signaling pathways crucial for cancer growth and progression.
• It is primarily used to treat advanced renal cell carcinoma (kidney cancer) and hepatocellular carcinoma (liver cancer).
• The medication works by inhibiting specific tyrosine kinases, thereby blocking tumor cell proliferation, metastasis, and angiogenesis.
• Dosage is typically once daily, with specific instructions regarding food intake and potential dose adjustments based on patient response and side effects.
• Common side effects include diarrhea, fatigue, and nausea, while more serious adverse events can occur, requiring close medical monitoring.

What is Cabometyx and How Does it Work?

Cabometyx refers to cabozantinib, an oral small-molecule tyrosine kinase inhibitor. It is a targeted therapy designed to interfere with specific molecular pathways that contribute to cancer development and progression. The medication is crucial in treating certain advanced cancers where these pathways are overactive.

How does Cabometyx work? Cabometyx works by inhibiting the activity of several receptor tyrosine kinases (RTKs) that are often dysregulated in cancer. Key targets include MET, VEGFR1, VEGFR2, VEGFR3, AXL, RET, ROS1, TYRO3, and KIT. By blocking these kinases, Cabometyx can disrupt various cellular processes essential for tumor growth, such as cell proliferation, angiogenesis (the formation of new blood vessels that feed tumors), and metastasis (the spread of cancer cells to other parts of the body). This multi-targeted approach helps to control tumor progression and improve patient outcomes in specific cancer types.

Cabometyx Uses and Dosage Information

What is Cabometyx used for? Cabometyx is approved for the treatment of specific advanced cancers. Its primary indications include:

• Advanced Renal Cell Carcinoma (RCC): For patients who have received prior anti-angiogenic therapy. It is also approved for first-line treatment of advanced RCC.
• Hepatocellular Carcinoma (HCC): For patients who have been previously treated with sorafenib.
• Differentiated Thyroid Cancer (DTC): For patients 12 years of age and older who have locally advanced or metastatic DTC that has progressed following prior VEGFR-targeted therapy and who are ineligible for or refractory to radioactive iodine.

Regarding Cabometyx dosage information, the typical recommended dose is 60 mg orally once daily for advanced RCC and HCC. For differentiated thyroid cancer, the recommended dose is 80 mg orally once daily. The tablets should not be crushed or chewed and should be taken on an empty stomach, at least 2 hours after and 1 hour before food. Dosage adjustments may be necessary based on individual patient tolerance and the occurrence of side effects, as determined by a healthcare professional. It is critical for patients to follow their doctor’s instructions precisely and not to alter their dose without medical advice.

Potential Cabometyx Side Effects

As with many potent cancer treatments, Cabometyx can cause a range of side effects, some of which can be serious. Awareness and management of these effects are vital for patient safety and treatment adherence. Common Cabometyx side effects often include:

• Diarrhea
• Fatigue
• Nausea and vomiting
• Decreased appetite
• Weight loss
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Hypertension (high blood pressure)
• Abdominal pain
• Dysgeusia (altered taste sensation)

More serious, though less common, side effects can occur and require immediate medical attention. These may include hemorrhage, gastrointestinal perforation or fistula, thrombotic events (blood clots), osteonecrosis of the jaw, proteinuria (protein in the urine), and reversible posterior leukoencephalopathy syndrome (RPLS). Patients should report any new or worsening symptoms to their healthcare provider promptly. Regular monitoring, including blood pressure checks and laboratory tests, is typically performed during treatment to manage potential adverse reactions effectively.